Search

Kevin D Ostrander

from Pawleys Island, SC
Age ~56
Get Report
Also known as:
Kevin S Ostrander, Ostrander Kevin
Related to:
Gloria J Ostrander, 73Christopher M Ostrander, 50Jack Wesdorp, 79Gary Ostrander, 72Donna Ostrander, 39
Connected to:
Adam G Ostrander, 50Aimee L Ostrander, 32Andrea L Ostrander, 38Anthony Ostrander, 61Ashly N Ostrander, 36Bobby D Ostrander, 77Brad A Ostrand, 51Catherine T Ostrander, 57Charles J Ostrand, 46Dana B Ostrander, 48

Kevin Ostrander Phones & Addresses

  • Pawleys Island, SC
  • Loris, SC
  • Myrtle Beach, SC
  • 174 Old York Rd, Ringoes, NJ 08551 (908) 591-1587
  • 227 Sunrise Rd, Reading, PA 19606
  • Memphis, TN
  • Vernon Hills, IL
  • Ballston Lake, NY
  • Schenectady, NY
  • 174 Old York Rd, Ringoes, NJ 08551

Publications

Us Patents

Liquid Droplet Aerosols Of Nanoparticulate Drugs

View page
US Patent:
6811767, Nov 2, 2004
Filed:
Jun 19, 2000
Appl. No.:
09/597738
Inventors:
H. William Bosch - Bryn Mawr PA
Kevin D. Ostrander - Reading PA
Eugene R. Cooper - Berwyn PA
Assignee:
Elan Pharma International Limited - Shannon
International Classification:
A61K 912
US Classification:
424 45, 424 46, 424489, 424426
Abstract:
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

Dry Powder Aerosols Of Nanoparticulate Drugs

View page
US Patent:
7521068, Apr 21, 2009
Filed:
Nov 12, 1998
Appl. No.:
09/190138
Inventors:
H. William Bosch - Bryn Mawr PA, US
Kevin D. Ostrander - Reading PA, US
Eugene R. Cooper - Berwyn PA, US
Assignee:
Elan Pharma International Ltd. - Dublin
International Classification:
A61K 8/00
A61K 9/14
A61K 9/16
A61K 31/12
A61K 31/04
A61K 31/28
A61K 31/33
A61K 31/56
A61K 31/70
A61K 38/00
A61K 38/02
US Classification:
424489, 424 46, 424490, 424491, 514 2, 514 23, 514169, 514182, 514826, 514851, 514872
Abstract:
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

Nanoparticulate Compositions Of Mitogen-Activated Protein (Map) Kinase Inhibitors

View page
US Patent:
7998507, Aug 16, 2011
Filed:
Dec 7, 2005
Appl. No.:
11/275069
Inventors:
H. William Bosch - Bryn Mawr PA, US
Greta G. Cary - Landsdale PA, US
Douglas C. Hovey - Gilbertsville PA, US
Rajeev A. Jain - Framingham MA, US
Laura J. Kline - Harleysville PA, US
Kevin D. Ostrander - Ringoes NJ, US
Niels P. Ryde - Malvern PA, US
Stephen B. Ruddy - Schwenksville PA, US
Assignee:
Elan Pharma International Ltd. - Athlone, County Westmeath
International Classification:
A61K 9/14
A61K 9/00
A61K 31/66
A61K 31/385
A61K 31/522
A61K 31/525
A61K 31/557
A61K 36/82
A61K 36/328
A61K 36/886
A61K 38/17
A61K 48/00
US Classification:
424489, 424729, 424744, 424748, 424768, 424776, 514 121, 514102, 514251, 51426331, 514440, 514561, 514573
Abstract:
Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Propellant-Based Nanoparticulate Dry Powder Aerosols And Method Of Making

View page
US Patent:
8124057, Feb 28, 2012
Filed:
Jan 26, 2009
Appl. No.:
12/320431
Inventors:
H. William Bosch - Bryn Mawr PA, US
Kevin D. Ostrander - Reading PA, US
Eugene R. Cooper - Berwyn PA, US
Assignee:
Alkermes Pharma Ireland Limited - County Westmeath
International Classification:
A61K 9/00
A61K 9/10
A61K 9/12
US Classification:
424 45
Abstract:
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.

Sterile Filtered Nanoparticulate Formulations Of Budesonide And Beclomethasone Having Tyloxapol As A Surface Stabilizer

View page
US Patent:
20030129242, Jul 10, 2003
Filed:
Jan 4, 2002
Appl. No.:
10/035324
Inventors:
H. Bosch - Bryn Mawr PA, US
Donna Marcera - Limerick PA, US
Kevin Ostrander - Reading PA, US
Niels Ryde - Malvern PA, US
Douglas White - King of Prussia PA, US
International Classification:
A61K031/573
A61L009/04
A61K009/14
US Classification:
424/489000, 514/179000, 424/046000
Abstract:
The invention relates to sterile filtered nanoparticulate compositions of beclomethasone and/or budesonide having as a surface stabilizer tyloxapol and, optionally, one or more secondary surface stabilizers adsorbed onto the surfaces thereof. The nanoparticulate compositions have an optimal effective average particle size of less than about 150 nm.

Nanoparticulate Compositions Of Mitogen-Activated Protein (Map) Kinase Inhibitors

View page
US Patent:
20030181411, Sep 25, 2003
Filed:
Mar 20, 2003
Appl. No.:
10/392303
Inventors:
H. Bosch - Bryn Mawr PA, US
Greta Cary - Lansdale PA, US
Douglas Hovey - Trooper PA, US
Rajeev Jain - Collegeville PA, US
Laura Kline - Harleysville PA, US
Kevin Ostrander - Ringoes NJ, US
Assignee:
Elan Pharma International Ltd.
International Classification:
A61K048/00
A61K031/551
US Classification:
514/044000, 514/220000
Abstract:
Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Novel Triamcinolone Compositions

View page
US Patent:
20040141925, Jul 22, 2004
Filed:
Oct 31, 2003
Appl. No.:
10/697716
Inventors:
H. Bosch - Bryn Mawr PA, US
Kevin Ostrander - Ringoes NJ, US
Eugene Cooper - Berwyn PA, US
Assignee:
Elan Pharma International Ltd.
International Classification:
A61L009/04
A61K009/14
US Classification:
424/046000, 424/489000
Abstract:
The invention is directed to nanoparticulate triamcinolone and/or triamcinolone derivative compositions. The triamcinolone or triamcinolone derivative particles of the composition have an effective average particle size of less than about 2 microns.

Dry Powder Aerosols Of Nanoparticulate Drugs

View page
US Patent:
20120213829, Aug 23, 2012
Filed:
Feb 24, 2012
Appl. No.:
13/404790
Inventors:
H. William Bosch - Bryn Mawr PA, US
Kevin D. Ostrander - Reading PA, US
Eugene R. Cooper - Berwyn PA, US
International Classification:
A61K 9/14
A61P 29/00
A61P 11/06
A61P 11/00
A61P 37/06
A61P 31/10
A61P 31/06
A61P 35/00
A61P 9/00
A61P 31/00
A61K 31/192
A61K 31/58
A61P 37/00
A61P 11/08
A61P 1/08
A61K 31/573
A61K 38/02
B82B 1/00
B82Y 5/00
US Classification:
424400, 424 43, 424 45, 977795, 977915, 977700
Abstract:
There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier on the surface thereof.
Control profile
Kevin D Ostrander from Pawleys Island, SC, age ~56 Get Report